Cleo Diagnostics

Cleo Diagnostics Current Liabilities

The Current Liabilities of Cleo Diagnostics (COV.AX) as of Nov 3, 2026 is 1.29 M AUD. In the previous year, Current Liabilities was 972,574.00 AUD — a change of 32.51% (higher).

Current Liabilities

1.29 MAUD

YoY

32.51%

Last updated:

Current Liabilities of Cleo Diagnostics is 2026 1.29 M AUD. Current Liabilities of Cleo Diagnostics was 2025 972,574.00 AUD. It decreases by 32.51% higher compared to the previous year.

The Cleo Diagnostics Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2022
240,680.00 AUD
Jan 1, 2023
2.02 M AUD
Jan 1, 2024
486,263.00 AUD
Jan 1, 2025
972,574.00 AUD
Jan 1, 2026
1.29 M AUD
The Cleo Diagnostics Current Liabilities history
YEARCurrent LiabilitiesYoY
1.29 MAUD+32.51%
972,574.00AUD+100.01%
486,263.00AUD-75.93%
2.02 MAUD+739.32%
240,680.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cleo Diagnostics Stock analysis

What does Cleo Diagnostics do? Cleo Diagnostics Ltd develops non-invasive blood-based IVD tests for ovarian cancer detection. The company's three-phased strategy includes the Triage Test for pre-surgical assessment of ovarian masses, the Recurrence Test for post-surgical monitoring of cancer recurrence, and the Screening Test for early detection in asymptomatic women. The CLEO Test Kit detects the protein biomarker CXCL10 in blood samples. These products target healthcare providers, oncologists, and diagnostic laboratories seeking advanced tools for ovarian cancer management. The company generates revenue through the sale of these diagnostic tests and kits to medical institutions and laboratories in Australia and potentially international markets. The Triage Test helps determine malignancy before oncologist referral, the Recurrence Test identifies cancer recurrence after surgery and chemotherapy, and the Screening Test enables early detection in symptom-free women. Cleo Diagnostics Ltd focuses on delivering these specialized tests to address unmet needs in ovarian cancer diagnostics. Revenue streams are derived from the commercialization of these three test phases and the CLEO Test Kit, targeting medical professionals and healthcare facilities requiring accurate and non-invasive diagnostic solutions. Cleo Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cleo Diagnostics stock

Current Liabilities of Cleo Diagnostics is 1.29 M AUD in 2026.

Current Liabilities of Cleo Diagnostics changed from 972,574.00 AUD to 1.29 M AUD, representing a 32.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Cleo Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Cleo Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Cleo Diagnostics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Cleo Diagnostics